SUMMARY All patients with a presumptive diagnosis of myocardial infarction, who were seen widtin six hours of the onset of symptoms and had no reason for exclusion, were considered for entry into a trial to compare the effects of metoprolol and placebo on creatine kinase MB isoenzyme release. The trial was randomised and double blind. The median time from onset of symptoms to receiving trial drug was just under two hours. Two hundred and four patients (of whom 120 had myocardial infarction) received metoprolol and 187 (of whom 105 had myocardial infarction) received placebo.
Intervention with beta adrenoceptor antagonists in patients who have sustained a myocardial infarction is generally accepted to reduce mortality when given some days after the acute event.'-3Few studies, however, have looked at the effect of very early intervention with beta adrenergic antagonists in the acute phase of myocardial infarction. Since patients with suspected acute myocardial infarction at the Ulster Hospital are usually seen by our mobile coronary care unit, we were in a unique position to assess the effect of early intervention. A theoretical benefit of early beta adrenergic blockade is reduction of infarct size.4 5 We report a study designed to test this hypothesis using the cardioselective beta adrenergic blocking drug metoprolol. Metoprolol has no partial agonist activity and no membrane stabilising activity. It has been used with safety during the acute stages of infarction.6
Patients and methods From 1 June 1979 to 31 January 1981, all patients with a presumptive diagnosis of myocardial infarction were considered for inclusion in the trial. Patients were excluded if: (1) there was a delay of more than six hours after the onset of symptoms; (2) there were clinical contraindications to the use of beta adrenergic Accepted for publication 26 November 1982 blocking drugs, that is heart block greater than first degree, clinical pulmonary oedema, cardiogenic shock, bradycardia with hypotension, or agonal rhythm; (3) the initial rhythm was ventricular fibrillation; (4) the following specified subgroups, depending on: (A) interval from onset of symptoms to intervention (<2 hours or ¢2 hours); (B) age (-65 years or >65 years); (C) initial heart rate (>100/minute,81-100/minute,or 680/minute); (D) site of infarction (anterior or inferior). The size of the trial was based on an expected reduction of enzyme release in the order of 25% in patients with infarction.5 It was estimated that 220 patients with myocardial infarction were needed and that the trial should stop as soon as it was known that at least 220 patients with myocardial infarction were included. Since there is a delay in confirming the diagnosis of infarction, 225 patients with myocardial infarction were entered.
Results
Three hundred and ninety-one patients received trial drug. Of these, 204 received metoprolol and 187 placebo. The difference in the group sizes is a result of the method of randomisation used, the admission of patients to the study more than once, and the accidental loss of a small number of ampoules. There were no significant differences between the two groups in terms of their admission characteristics ( (Table 2) . Forty-four patients in the metoprolol group had inferior infarction. The mean release of creatine kinase MB isoenzyme was 383 IU/1. Thirty-eight patients in the placebo group, and who had inferior infarction, had a mean release of 506 IU/1. This represents a reduction in infarct size of 24% and was statistically significant (p<0 05). In each of the subgroups about two thirds of the patients were 65 years or less, so that reduction in infarct size in patients with inferior infarction appeared to be independent of age. In the other subgroups examined, no significant reduction in creatine kinase MB isoenzyme was found (Table 2) .
ACUTE CLINICAL RESPONSE
Clinical problems related to early intravenous metoprolol were uncommon. Trial drug was stopped in hospital because of possible adverse effects in 370/o of patients with myocardial infarction after receiving metoprolol and in 300/o of those receiving placebo. The difference is not statistically significant. The incidence of possible adverse reactions which led to withdrawal of the trial drug is given in Table 3 . Heart failure, defined as radiological evidence of interstitial or acute alveolar oedema, occurred in 14% of patients irrespective of their receiving metoprolol or placebo. Severe In studies of this kind, the most relevant finding is that applicable to the entire group, rather than to subgroups. In our study, there was an apparent reduction of creatine kinase MB isoenzyme release of 14%. The value of p lay between 0.05 and 0.1, so that statistical significance was not achieved. This finding must be looked at in the context of other studies in which a beta adrenergic blocking drug is given intravenously in the early hours after myocardial infarction.
Decisions on the benefit of clinical intervention are frequently based on pooled data of available series. Bias is introduced in pooling if negative studies are not available for comparison. Our results are consistent with other published studies,5 '5-'7 suggesting a true reduction of enzyme release (Table 4) .
Subgroup analysis, even when the subgroups are defined at the outset of the study, increases the chance of spurious significant differences but does give a basis for hypotheses to be tested. Our results suggest that a reduction in enzyme release is more likely to occur in the younger age group. This is in contrast to 
